更新于：2024-11-21

Influenza Virus Like Particle Vaccines(University Of Washington)

更新于：2024-11-21

概要

研发状态

概要

基本信息

药物类型

病毒样颗粒疫苗、预防性疫苗

别名

Influenza VLP vaccines - Icosavax、Research programme: influenza virus like particle vaccines - Icosavax、influenza virus like particle vaccines(University of Washington)

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症

流感病毒感染

非在研适应症-

原研机构

University of Washington

在研机构

Icosavax, Inc.

National Institutes of Health

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Influenza Virus Like Particle Vaccines(University Of Washington) 相关的临床结果

登录后查看更多信息

100 项与 Influenza Virus Like Particle Vaccines(University Of Washington) 相关的转化医学

登录后查看更多信息

100 项与 Influenza Virus Like Particle Vaccines(University Of Washington) 相关的专利（医药）

登录后查看更多信息

项与 Influenza Virus Like Particle Vaccines(University Of Washington) 相关的文献（医药）

2018-09-02·Expert Review of Vaccines2区 · 医学

Virus-like particle vaccines: immunology and formulation for clinical translation

2区 · 医学

Review

作者: Lateef, Zabeen ; Walker, Greg F. ; Donaldson, Braeden ; Young, Sarah L. ; Ward, Vernon K.

INTRODUCTIONVirus-like particle (VLP) vaccines face significant challenges in their translation from laboratory models, to routine clinical administration. While some VLP vaccines thrive and are readily adopted into the vaccination schedule, others are restrained by regulatory obstacles, proprietary limitations, or finding their niche amongst the crowded vaccine market. Often the necessity to supplant an existing vaccination regimen possesses an immediate obstacle for the development of a VLP vaccine, despite any preclinical advantages identified over the competition. Novelty, adaptability and formulation compatibility may prove invaluable in helping place VLP vaccines at the forefront of vaccination technology.AREAS COVEREDThe purpose of this review is to outline the diversity of VLP vaccines, VLP-specific immune responses, and to explore how modern formulation and delivery techniques can enhance the clinical relevance and overall success of VLP vaccines.EXPERT COMMENTARYThe role of formation science, with an emphasis on the diversity of immune responses induced by VLP, is underrepresented amongst clinical trials for VLP vaccines. Harnessing such diversity, particularly through the use of combinations of select excipients and adjuvants, will be paramount in the development of VLP vaccines.

2018-07-15·Journal of Virology2区 · 医学

Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines

2区 · 医学

Article

作者: Überla, Klaus ; Khoo, Keith K. ; Mak, Johnson ; Temchura, Vladimir ; Salazar, Andres M. ; McKinstry, William J. ; Nabi, Ghulam ; Elsayed, Hassan ; Tenbusch, Matthias

ABSTRACTInduction of persistent antibody responses by vaccination is generally thought to depend on efficient help by T follicular helper cells. Since the T helper cell response to HIV Env may not be optimal, we explored the possibility of improving the HIV Env antibody response to virus-like particle (VLP) vaccines by recruiting T helper cells induced by commonly used licensed vaccines to provide help for Env-specific B cells. B cells specific for the surface protein of a VLP can internalize the entire VLP and thus present peptides derived from the surface and core proteins on their major histocompatibility complex class II (MHC-II) molecules. This allows T helper cells specific for the core protein to provide intrastructural help for B cells recognizing the surface protein. Consistently, priming mice with an adjuvanted Gag protein vaccine enhanced the HIV Env antibody response to subsequent booster immunizations with HIV VLPs. To harness T helper cells induced by the licensed Tetanolpur vaccines, HIV VLPs that contained T helper cell epitopes of tetanus toxoid were generated. Tetanol-immunized mice raised stronger antibody responses to immunizations with VLPs containing tetanus toxoid T helper cell epitopes but not to VLPs lacking these epitopes. Depending on the priming immunization, the IgG subtype response to HIV Env after the VLP immunization could also be modified. Thus, harnessing T helper cells induced by other vaccines appears to be a promising approach to improve the HIV Env antibody response to VLP vaccines.IMPORTANCEInduction of HIV Env antibodies at sufficient levels with optimal Fc effector functions for durable protection remains a challenge. Efficient T cell help may be essential to induce such a desirable antibody response. Here, we provide proof of concept that T helper cells induced by a licensed vaccine can be harnessed to provide help for HIV Env-specific B cells and to modulate the Env-specific IgG subtype response.

2017-12-01·Microbes and Infection3区 · 医学

Blockage of regulatory T cells augments induction of protective immune responses by influenza virus-like particles in aged mice

3区 · 医学

Article

作者: Yang, Chinglai ; Ye, Ling ; Wen, Zhiyuan ; Dong, Ke ; Bu, Zhigao ; Zhang, Huizhong ; Wang, Xi

Elderly humans over 65 years old are at great risk to pathogenesis by influenza virus infection. However, although influenza vaccines provide effective protection in healthy young adults, protection of elderly adults is substantially lower even with a good match between the vaccine and the circulating influenza virus. To gain insight of the underlying mechanism for the reduced immunogenicity of influenza vaccines in the aged population, we investigated immunogenicity of influenza virus-like particle vaccines in aged mice, which represent a useful model for studying aging associated impairment in immune responses. Specifically, we investigated the effect of inhibiting regulatory T cells in aged mice on induction of protective immune responses by influenza vaccines. Our results showed that injecting anti-CD25 antibodies could down-regulate CD25 on the surface of regulatory T cells and significantly increase the levels of antibody responses induced by VLP immunization in aged mice. Further, the profiles of antibody responses were also changed towards Th1 type by regulatory T cell blockage in aged mice. Moreover, aged mice that were treated by anti-CD25 antibodies prior to vaccination were more effectively protected against lethal influenza virus challenge.

项与 Influenza Virus Like Particle Vaccines(University Of Washington) 相关的新闻（医药）

2023-08-14

·BioSpace

Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update

- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept for revaccination with IVX-121 against RSV - - Initiation of Phase 2 Trial of IVX-A12 with topline interim results now expected by end 2023 - - Closed $67.8 million registered direct offering of common stock; extended cash runway into 2H 2025 - SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The first half of 2023 has been particularly productive for Icosavax, highlighted by our positive topline interim Phase 1 data and the initiation of a Phase 2 trial for IVX-A12, our potential first-in-class bivalent vaccine candidate for RSV and hMPV,” said Adam Simpson, Chief Executive Officer of Icosavax. “From our Phase 1b extension trial of IVX-121 in RSV, we recently announced positive 12-month immunogenicity and initial revaccination data; these were exciting because better durability and improved response to boosting are potential opportunities for differentiation of our VLP technology. Looking ahead we have additional near-term clinical milestones, including topline interim data from our Phase 2 study of IVX-A12 by the end of the year.” Second Quarter 2023 and Subsequent Highlights Reported positive topline interim phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults. In May 2023, Icosavax announced positive topline interim results from a Phase 1 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults. IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavax’s hMPV prefusion F protein VLP vaccine candidate. In this Phase 1 trial, IVX-A12 induced robust immune responses against both RSV and hMPV at day 28 in older adults, with no evidence of immune interference between RSV and hMPV VLPs administered in combination, and was generally well-tolerated across all dosage groups. Initiated Phase 2 clinical trial of IVX-A12 against RSV and hMPV in older adults. In June 2023, Icosavax announced the initiation of a Phase 2 clinical trial of IVX-A12 in older adults. Dosing has been completed and topline interim data is now expected by the end of 2023. Reported positive 12-month durability data for IVX-121 against RSV and initial evidence for revaccination potential. In August 2023, Icosavax provided a 12-month immunogenicity update from its Phase 1b extension trial of IVX-121 against RSV in older adults. These data demonstrate substantial durability of neutralizing antibody (NAb) response against RSV at twelve months after a single administration of IVX-121. The company also reported initial evidence for revaccination potential with its VLP-based vaccines, including robust immune responses against RSV-A in Phase 1b extension trial participants who received 75 µg unadjuvanted IVX-121 at one year after their first dose. Completed a $67.8 million registered direct offering of common stock. In May 2023, Icosavax closed a registered direct offering of 8,369,754 shares of its common stock at a purchase price of $8.10 per share. The $67.8 million financing was led by new investor TCGX with participation by additional new investors including Logos Capital and Vivo Capital. Appointed Dr. M. Amin Khan, PhD as Executive Vice President, Head of Research and Development. During the quarter, Icosavax appointed Dr. M. Amin Khan as the company’s Head of Research and Development. Dr. Khan has more than 30 years’ experience in vaccine and pharmaceutical R&D, including senior scientific and executive leadership roles at Eli Lilly, Novartis and GlaxoSmithKline. He has guided scientific and technical teams to develop novel vaccines for infectious diseases including targets for RSV, influenza, meningitis, group B streptococcus, S. aureus, COPD, CMV, herpes zoster and SARS-Cov-2, and has contributed to the licensure of four vaccines. Near-Term Milestone Expectations IVX-A12 (RSV + hMPV) Phase 2 topline interim data expected by end 2023 IVX-A12 (RSV+ hMPV) Phase 1 six-month immunogenicity data expected in 1Q 2024 Other indications: no changes to milestones related to Flu and COVID-19 programs Second Quarter Financial Results Cash and cash equivalents and short-term investments as of June 30, 2023 was $246.9 million, compared to $219.4 million for the period ended December 31, 2022. Icosavax currently expects its cash balance to be sufficient to fund operations into 2H 2025. Research and development (R&D) expenses for the three months ended June 30, 2023 were $19.9 million, compared to $15.8 million for the same period in 2022. The increase was primarily driven by increased clinical development activity, increased personnel related expenses and stock-based compensation expense, increased expenses primarily related to facilities costs, and increased development-related consulting costs, partially offset by decreased preclinical development and manufacturing activity. Research and development expenses include non-cash stock-based compensation expenses of $2.4 million for the three months ended June 30, 2023. General and administrative (G&A) expenses for the three months ended June 30, 2023 were $9.1 million compared to $7.3 million for the same period in 2022. The increase was primarily due to increased expenses related to facilities costs to support the company’s growth, increased stock-based compensation expense, increased professional services, and growth in the number of G&A employees. General and administrative expenses include non-cash stock-based compensation expenses of $3.9 million for the three months ended June 30, 2023. Net loss for the three months ended June 30, 2023 was $26.5 million, or a basic and diluted net loss per share of $0.59. This includes non-cash stock-based compensation expense of $6.3 million. Net loss for the same period in 2022 was $22.6 million or a basic and diluted net loss per share of $0.57. About Icosavax Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle. For more information, visit Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations and include, but are not limited to: the company’s expectation regarding the opportunities for, and the prophylactic and commercial potential of, its vaccine candidates and technology platform, including the potential for IVX-A12 to be a first-in-class vaccine; the company’s ability to advance its development program and achieve the noted development milestones in 2023; and the sufficiency of the company’s current cash, cash equivalents and investments to fund its operations into 2H 2025. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the company’s business, including, without limitation: the early stage of the company’s development efforts; the company’s approach to the development of vaccine candidates, including its development of a combination bivalent RSV/hMPV VLP vaccine candidate, which is a novel and unproven approach; potential delays in the development process including without limitation in the commencement, enrollment, conduct of, and receipt of data from, clinical trials; difficulties in developing an hMPV challenge model and the risk that the planned challenge study may produce negative or inconclusive results based on such model or otherwise; unexpected adverse side effects or inadequate immunogenicity or efficacy of the company’s vaccine candidates that may limit their development, regulatory approval, and/or commercialization; the company’s dependence on third parties in connection with manufacturing, research, and clinical testing; the risk that approved third party RSV vaccines may make conducting clinical trials more difficult and costly and otherwise adversely affect the company’s ability to successfully develop, obtain regulatory approval of and commercialize its vaccine candidates; approved vaccines and competing approaches limiting the commercial value of the company’s vaccine candidates; regulatory developments in the United States and other countries; the company’s ability to fund its operating plans with its current cash, cash equivalents and investments; and other risks described in the company’s prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s quarterly report on Form 10-Q for the quarter ended March 31, 2023 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Icosavax’s Contacts Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc. jessica@litldog.com 858.344.8091 Investor Contact: Laurence Watts Gilmartin Group, LLC laurence@gilmartinir.com 619.916.7620 ICOSAVAX, INC. Condensed Balance Sheets (Unaudited) (in thousands) June 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 155,073 $ 58,846 Restricted cash - 1,061 Short-term investments 91,860 159,461 Prepaid expenses and other current assets 4,766 4,545 Total current assets 251,699 223,913 Right-of-use assets - operating leases 3,072 3,247 Property and equipment, net 12,131 11,517 Other noncurrent assets 2,124 - Total assets $ 269,026 $ 238,677 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,547 $ 2,892 Accrued and other current liabilities 11,298 8,759 Current portion of operating lease liabilities 2,169 2,137 Total current liabilities 15,014 13,788 Operating lease liabilities, net of current portion 6,272 6,658 Other noncurrent liabilities 18 69 Total liabilities 21,304 20,515 Stockholders' equity: Common stock 7 6 Additional paid-in capital 484,666 404,386 Accumulated other comprehensive loss (66 ) (403 ) Accumulated deficit (236,885 ) (185,827 ) Total stockholders' equity 247,722 218,162 Total liabilities and stockholders' equity $ 269,026 $ 238,677 ICOSAVAX, INC. Condensed Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Grant revenue $ - $ - $ - $ 582 Operating expenses: Research and development 19,826 15,820 37,183 33,733 General and administrative 9,129 7,311 18,294 13,633 Total operating expenses 28,955 23,131 55,477 47,366 Loss from operations (28,955 ) (23,131 ) (55,477 ) (46,784 ) Other income: Interest and other income 2,458 495 4,419 615 Total other income 2,458 495 4,419 615 Net loss $ (26,497 ) $ (22,636 ) $ (51,058 ) $ (46,169 ) Other comprehensive (loss) income: Unrealized (losses) gains on available-for-sale debt securities (3 ) (275 ) 337 (275 ) Comprehensive loss $ (26,500 ) $ (22,911 ) $ (50,721 ) $ (46,444 ) Net loss per share, basic and diluted $ (0.59 ) $ (0.57 ) $ (1.19 ) $ (1.17 ) Weighted-average common shares outstanding, basic and diluted 44,770,820 39,594,028 43,042,461 39,524,408

疫苗临床1期财报临床结果临床2期

2023-08-03

·MedCity News

GSK Patent Suit Aims to Halt Pfizer’s RSV Vaccine for Adults, But Not Infants

The respiratory syncytial virus season is months away, but competition between the only two approved vaccines (so far) for the pathogen is already heating up. GSK is suing Pfizer, claiming that company’s vaccine infringes on four of its patents. The GSK vaccine for RSV, Arexvy, and Pfizer’s vaccine, Abrysvo are both new products, having won their FDA approvals in May for preventing the lower respiratory tract disease caused by RSV in adults 60 and older, an age group particularly vulnerable to the pathogen. GSK’s approval was first. In the complaint filed on Wednesday in federal court for the Delaware District (case number 23-cv-831), GSK now claims it was also sooner to begin RSV vaccine research. Other research predated GSK’s work. The complaint notes 1960s efforts that failed with inactivated virus, live-attenuated virus, and vaccines that target specific proteins in the pathogen. Recent RSV vaccine research has focused on RSV F, a protein that the virus uses to fuse to and enter cells, causing infection. In the early 2000s, scientists at the National Institute for Allergy and Infectious Diseases identified two versions of the protein, a prefusion form and a postfusion form. The prefusion form was shown to be better at eliciting antibodies that confer protection, so this is the version that became the basis for much RSV vaccine research. Pfizer’s Abrysvo has two versions of a prefusion form of the F protein. As Pfizer reported clinical trial progress for that vaccine and provided updates on the regulatory process, the pharmaceutical giant said its vaccine builds on the NIH research. Other companies, such as Moderna and Icosavax, are also developing RSV vaccines that address this conformation of the F protein. GSK’s complaint makes no reference to the NIH research but claims its own RSV work dates to the early 2000s. The British pharma giant says Pfizer’s research started in 2013—at least seven years after GSK. The company goes on to say that its scientists focused on RSVPreF, the prefusion form of the protein. “GSK scientists realized that previous vaccines using the RSVPostF conformation induced an immune response only to the RSVPostF conformation, which induced an immune response only to the RSVPostF conformation, which led to limited or no efficacy,” GSK said in the complaint. “Beginning in the mid-2000s and continuing into this decade, GSK scientists worked to develop an RSVPreF antigen that targets the RSVPreF conformation present on the virus before it attaches to the cell surface.” GSK said it patented compositions of RSV vaccines and methods for preparing those compositions. According to GSK, Pfizer knew of at least one of them, a patent for recombinant RSV antigens. In 2019, Pfizer filed an opposition with the European Patent Office claiming the European counterpart of that patent is invalid, the complaint said. Pfizer also claimed that patent and another one were invalid in 2022 actions filed in London. In an emailed statement, Pfizer confirmed that GSK initiated litigation in federal court asserting patent infringement related to RSV vaccines. “Pfizer is confident in its intellectual property position and will strongly defend its right to bring its innovative RSV vaccine Abrysvo to patients,” the company said. In addition to clinical research in older adults, Abrysvo was tested as a maternal vaccine that protects an infant through vaccination of the mother during pregnancy. Antibodies produced by the mother’s immune system pass through the placenta and confer protection to the fetus. In May, an FDA advisory committee voted unanimously that clinical data support the vaccine’s effectiveness in infants. An FDA decision for Abrysvo as a maternal vaccine is expected later this month. GSK is seeking an unspecified amount in damages that include lost profits and royalties from Pfizer’s alleged patent infringement. That sum could be increased to triple the amount found, plus interest, according to the complaint. GSK is also asking for an order that permanently stops Pfizer from making or selling its RSV vaccine in the U.S. for adults over 60. The company stopped short of seeking to restrain Abrysvo’s use for preventing RSV disease in infants. But GSK still sees this use as an infringement and it “will seek appropriate damages or other monetary relief in lieu of an injunction for such infringing use,” the complaint said. Public domain image by the CDC

疫苗专利侵权上市批准信使RNA

2023-05-22

·GlobeNewswire-Health Care

Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock

SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 8,369,754 shares of its common stock at a purchase price of $8.10 per share. The financing was led by new investor TCGX with participation by additional new investors including Logos Capital and Vivo Capital. All of the shares are to be sold by Icosavax. Icosavax expects to receive gross proceeds of approximately $67.8 million from the offering. The offering is expected to close on May 25, 2023, subject to customary closing conditions. The shares were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-266894) that was previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on August 29, 2022. A final prospectus supplement, which contains additional information relating to the offering, will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Icosavax Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle. For more information, visit www.icosavax.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations and include, but are not limited to limitation statements regarding the company’s expectations on the completion, timing and size of the offering. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in the company’s business described in the company’s prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s quarterly report on Form 10-Q for the quarter ended March 31, 2023 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Icosavax’s Contacts Media Contact:Jessica Yingling, Ph.D.,Little Dog Communications Inc.jessica@litldog.com858.344.8091 Investor Contact:Laurence WattsGilmartin Group, LLClaurence@gilmartinir.com619.916.7620

疫苗临床研究

100 项与 Influenza Virus Like Particle Vaccines(University Of Washington) 相关的药物交易

登录后查看更多信息